PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35604090-10	2022	Mechanically, bilirubin inhibited sorafenib-induced activation of GSK-3beta and subsequent downstream MCL-1 degradation.	Sorafenib	34-43	glycogen synthase kinase 3 alpha	Homo sapiens	66-75	
34950583-0	2021	SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3beta/CTNNB1 Pathway.	Sorafenib	61-70	glycogen synthase kinase 3 alpha	Homo sapiens	112-120	
34950583-9	2021	Conclusion: SENP2 suppresses HCC stemness and increases sorafenib sensitivity through inactivating the AKT/GSK3beta/CTNNB1 signaling pathway.	Sorafenib	56-65	glycogen synthase kinase 3 alpha	Homo sapiens	107-115	
32391926-8	2022	Mechanistic study revealed that sorafenib decreased phosphorylation of serine 9 (S9) of GSK3beta, while increased phosphorylation of tyrosine 216 (Y216) of GSK3beta.	Sorafenib	32-41	glycogen synthase kinase 3 alpha	Homo sapiens	88-96	
33735117-0	2021	Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3beta signaling axis in hepatocellular carcinoma cells.	Sorafenib	67-76	glycogen synthase kinase 3 alpha	Homo sapiens	90-99	
33735117-7	2021	In addition, vinpocetine plus sorafenib activates glycogen synthase kinase 3beta (GSK-3beta) and subsequently inhibits cytoprotective autophagy induced by vinpocetine in HCC cells.	Sorafenib	30-39	glycogen synthase kinase 3 alpha	Homo sapiens	82-91	
33735117-8	2021	Meanwhile, overexpression of GSK-3beta was efficient to increase the apoptosis induced by vinpocetine plus sorafenib in HCC cells.	Sorafenib	107-116	glycogen synthase kinase 3 alpha	Homo sapiens	29-38	
33735117-9	2021	Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3beta and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3beta signaling axis.	Sorafenib	41-50	glycogen synthase kinase 3 alpha	Homo sapiens	189-198	
33735117-9	2021	Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3beta and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3beta signaling axis.	Sorafenib	41-50	glycogen synthase kinase 3 alpha	Homo sapiens	313-322	
32391926-8	2022	Mechanistic study revealed that sorafenib decreased phosphorylation of serine 9 (S9) of GSK3beta, while increased phosphorylation of tyrosine 216 (Y216) of GSK3beta.	Sorafenib	32-41	glycogen synthase kinase 3 alpha	Homo sapiens	156-164	
32391926-9	2022	These results suggest that sorafenib activates the beta-catenin signaling through the regulation of GSK3beta phosphorylation, thereby affecting the pigmentation process.	Sorafenib	27-36	glycogen synthase kinase 3 alpha	Homo sapiens	100-108